Global Parkinson’s Disease Therapeutics Market

Parkinson’s Disease Therapeutics Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Route of Administration (Oral, Parental (Rectal, Intranasal, Sublingual), Intravenous injection., Others), Drug Class (Levodopa/carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics, Other) Players and Region - Global Market Outlook to 2026

Parkinson’s Disease Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
The study covers a detailed analysis segmented by key business segments i.e. and major geographies.

What is Parkinson’s Disease Therapeutics?
Parkinson's disease is a progressive nervous system condition that affects people's ability to move. Parkinson's disease symptoms begin slowly, with tremors in one hand that are barely visible. Stiffness, rigid muscles, impaired posture and balance, lack of automatic movement, and slowing of movement are common symptoms of the disease. While Parkinson's disease cannot be entirely cured, drugs can help to alleviate the symptoms. Parkinson's disease is an idiopathic disease that develops for no apparent reason. Only symptomatic drug therapies are currently available on the market. Furthermore, these effects are detected at a later point, when the majority of the dopamine-producing cells have stopped working. This scenario suggests that innovative drugs will be needed in the near future. The demand is being driven by two major factors: an ageing population and an increase in the incidence of neurodegenerative diseases. Furthermore, rising R&D spending and the number of drugs in development are expected to boost market growth. Recent advancements in Parkinson's disease therapeutics, such as combination therapies to extend the action of continuous dopaminergic stimulation medications, approval of neurostimulation devices as neuroprotective therapies to delay disease progression, gene therapy, neural transplantation, and others, are expected to drive massive growth in the global Parkinson's disease therapeutics market.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Parkinson’s Disease Therapeutics market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • Optimus Pharma (India)
  • Teva (Israel)
  • AbbVie (United States)
  • Boehringer Ingelheim (Germany)
  • Lundbeck (Denmark)
  • Acadia (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Sun Pharma (India)
  • Cipla (India)
  • Dr. Reddy’s (India)


Market Trend
Carbidopa-levodopa Therapy is the Most Effective and the Most Used Medication
Restraints
  • High Cost of Treatment
  • Lack of Expertise for Early Diagnosis

Opportunities
Technological Advancements In Treatment Procedure and Increasing Investment in R&D in Healthcare Industry

Key highlights of the Global Parkinson’s Disease Therapeutics market Study:
• CAGR of the market during the forecast period 2020-2026
• In-depth information on growth factors that will accelerate the Parkinson’s Disease Therapeutics market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Parkinson’s Disease Therapeutics market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Parkinson’s Disease Therapeutics Players

Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Parkinson’s Disease Therapeutics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Parkinson’s Disease Therapeutics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Manufacturers of Parkinson's Drugs, Suppliers of Parkinson's Drugs, Wholesalers, Distributors and Retailers of Parkinson's Drugs, Pharmaceutical Companies, Medical Research Institutes and Governmental bodies.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Distribution Channel
  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies

By Route of Administration
  • Oral
  • Parental (Rectal, Intranasal, Sublingual)
  • Intravenous injection.
  • Others

By Drug Class
  • Levodopa/carbidopa
  • Dopamine Receptor Agonists
  • MAO-Inhibitors
  • COMT-inhibitors
  • Anticholinergics
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Geriatric Population and Burden of Parkinson's Disease
      • 3.2.2. Growing Awareness Among the Population
    • 3.3. Market Challenges
      • 3.3.1. Various Regulatory Factors for Drug Approval
    • 3.4. Market Trends
      • 3.4.1. Carbidopa-levodopa Therapy is the Most Effective and the Most Used Medication
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Parkinson’s Disease Therapeutics, by Distribution Channel, Route of Administration , Drug Class and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Parkinson’s Disease Therapeutics (Value)
      • 5.2.1. Global Parkinson’s Disease Therapeutics by: Distribution Channel (Value)
        • 5.2.1.1. Hospital Pharmacies
        • 5.2.1.2. Retailer Pharmacies
        • 5.2.1.3. Online Pharmacies
      • 5.2.2. Global Parkinson’s Disease Therapeutics by: Drug Class (Value)
        • 5.2.2.1. Levodopa/carbidopa
        • 5.2.2.2. Dopamine Receptor Agonists
        • 5.2.2.3. MAO-Inhibitors
        • 5.2.2.4. COMT-inhibitors
        • 5.2.2.5. Anticholinergics
        • 5.2.2.6. Other
      • 5.2.3. Global Parkinson’s Disease Therapeutics Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Parkinson’s Disease Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Optimus Pharma (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lundbeck (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Acadia (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sun Pharma (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cipla (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dr. Reddy’s (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Parkinson’s Disease Therapeutics Sale, by Distribution Channel, Route of Administration , Drug Class and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Parkinson’s Disease Therapeutics (Value)
      • 7.2.1. Global Parkinson’s Disease Therapeutics by: Distribution Channel (Value)
        • 7.2.1.1. Hospital Pharmacies
        • 7.2.1.2. Retailer Pharmacies
        • 7.2.1.3. Online Pharmacies
      • 7.2.2. Global Parkinson’s Disease Therapeutics by: Drug Class (Value)
        • 7.2.2.1. Levodopa/carbidopa
        • 7.2.2.2. Dopamine Receptor Agonists
        • 7.2.2.3. MAO-Inhibitors
        • 7.2.2.4. COMT-inhibitors
        • 7.2.2.5. Anticholinergics
        • 7.2.2.6. Other
      • 7.2.3. Global Parkinson’s Disease Therapeutics Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Parkinson’s Disease Therapeutics: by Distribution Channel(USD Million)
  • Table 2. Parkinson’s Disease Therapeutics Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 3. Parkinson’s Disease Therapeutics Retailer Pharmacies , by Region USD Million (2015-2020)
  • Table 4. Parkinson’s Disease Therapeutics Online Pharmacies , by Region USD Million (2015-2020)
  • Table 5. Parkinson’s Disease Therapeutics: by Drug Class(USD Million)
  • Table 6. Parkinson’s Disease Therapeutics Levodopa/carbidopa , by Region USD Million (2015-2020)
  • Table 7. Parkinson’s Disease Therapeutics Dopamine Receptor Agonists , by Region USD Million (2015-2020)
  • Table 8. Parkinson’s Disease Therapeutics MAO-Inhibitors , by Region USD Million (2015-2020)
  • Table 9. Parkinson’s Disease Therapeutics COMT-inhibitors , by Region USD Million (2015-2020)
  • Table 10. Parkinson’s Disease Therapeutics Anticholinergics , by Region USD Million (2015-2020)
  • Table 11. Parkinson’s Disease Therapeutics Other , by Region USD Million (2015-2020)
  • Table 12. South America Parkinson’s Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 13. South America Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 14. South America Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 15. South America Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 16. Brazil Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 17. Brazil Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 18. Brazil Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 19. Argentina Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 20. Argentina Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 21. Argentina Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 22. Rest of South America Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 23. Rest of South America Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 24. Rest of South America Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 25. Asia Pacific Parkinson’s Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 27. Asia Pacific Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 28. Asia Pacific Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 29. China Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 30. China Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 31. China Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 32. Japan Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 33. Japan Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 34. Japan Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 35. India Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 36. India Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 37. India Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 38. South Korea Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 39. South Korea Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 40. South Korea Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 41. Taiwan Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 42. Taiwan Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 43. Taiwan Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 44. Australia Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 45. Australia Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 46. Australia Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 50. Europe Parkinson’s Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 51. Europe Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 52. Europe Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 53. Europe Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 54. Germany Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 55. Germany Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 56. Germany Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 57. France Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 58. France Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 59. France Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 60. Italy Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 61. Italy Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 62. Italy Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 63. United Kingdom Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 64. United Kingdom Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 65. United Kingdom Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 66. Netherlands Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 67. Netherlands Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 68. Netherlands Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 69. Rest of Europe Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 70. Rest of Europe Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 71. Rest of Europe Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 72. MEA Parkinson’s Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 73. MEA Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 74. MEA Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 75. MEA Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 76. Middle East Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 77. Middle East Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 78. Middle East Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 79. Africa Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 80. Africa Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 81. Africa Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 82. North America Parkinson’s Disease Therapeutics, by Country USD Million (2015-2020)
  • Table 83. North America Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 84. North America Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 85. North America Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 86. United States Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 87. United States Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 88. United States Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 89. Canada Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 90. Canada Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 91. Canada Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 92. Mexico Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 93. Mexico Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 94. Mexico Parkinson’s Disease Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Parkinson’s Disease Therapeutics: by Distribution Channel(USD Million)
  • Table 106. Parkinson’s Disease Therapeutics Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 107. Parkinson’s Disease Therapeutics Retailer Pharmacies , by Region USD Million (2021-2026)
  • Table 108. Parkinson’s Disease Therapeutics Online Pharmacies , by Region USD Million (2021-2026)
  • Table 109. Parkinson’s Disease Therapeutics: by Drug Class(USD Million)
  • Table 110. Parkinson’s Disease Therapeutics Levodopa/carbidopa , by Region USD Million (2021-2026)
  • Table 111. Parkinson’s Disease Therapeutics Dopamine Receptor Agonists , by Region USD Million (2021-2026)
  • Table 112. Parkinson’s Disease Therapeutics MAO-Inhibitors , by Region USD Million (2021-2026)
  • Table 113. Parkinson’s Disease Therapeutics COMT-inhibitors , by Region USD Million (2021-2026)
  • Table 114. Parkinson’s Disease Therapeutics Anticholinergics , by Region USD Million (2021-2026)
  • Table 115. Parkinson’s Disease Therapeutics Other , by Region USD Million (2021-2026)
  • Table 116. South America Parkinson’s Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 117. South America Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 118. South America Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 119. South America Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 120. Brazil Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 121. Brazil Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 122. Brazil Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 123. Argentina Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 124. Argentina Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 125. Argentina Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 126. Rest of South America Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 127. Rest of South America Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 128. Rest of South America Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 129. Asia Pacific Parkinson’s Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 130. Asia Pacific Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 131. Asia Pacific Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 132. Asia Pacific Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 133. China Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 134. China Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 135. China Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 136. Japan Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 137. Japan Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 138. Japan Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 139. India Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 140. India Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 141. India Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 142. South Korea Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 143. South Korea Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 144. South Korea Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 145. Taiwan Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 146. Taiwan Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 147. Taiwan Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 148. Australia Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 149. Australia Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 150. Australia Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 154. Europe Parkinson’s Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 155. Europe Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 156. Europe Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 157. Europe Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 158. Germany Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 159. Germany Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 160. Germany Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 161. France Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 162. France Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 163. France Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 164. Italy Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 165. Italy Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 166. Italy Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 167. United Kingdom Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 168. United Kingdom Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 169. United Kingdom Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 170. Netherlands Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 171. Netherlands Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 172. Netherlands Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 173. Rest of Europe Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 174. Rest of Europe Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 175. Rest of Europe Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 176. MEA Parkinson’s Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 177. MEA Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 178. MEA Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 179. MEA Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 180. Middle East Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 181. Middle East Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 182. Middle East Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 183. Africa Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 184. Africa Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 185. Africa Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 186. North America Parkinson’s Disease Therapeutics, by Country USD Million (2021-2026)
  • Table 187. North America Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 188. North America Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 189. North America Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 190. United States Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 191. United States Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 192. United States Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 193. Canada Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 194. Canada Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 195. Canada Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 196. Mexico Parkinson’s Disease Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 197. Mexico Parkinson’s Disease Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 198. Mexico Parkinson’s Disease Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Parkinson’s Disease Therapeutics: by Distribution Channel USD Million (2015-2020)
  • Figure 5. Global Parkinson’s Disease Therapeutics: by Drug Class USD Million (2015-2020)
  • Figure 6. South America Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 7. Asia Pacific Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 8. Europe Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 9. MEA Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 10. North America Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 11. Global Parkinson’s Disease Therapeutics share by Players 2020 (%)
  • Figure 12. Global Parkinson’s Disease Therapeutics share by Players (Top 3) 2020(%)
  • Figure 13. Global Parkinson’s Disease Therapeutics share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Optimus Pharma (India) Revenue, Net Income and Gross profit
  • Figure 16. Optimus Pharma (India) Revenue: by Geography 2020
  • Figure 17. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 18. Teva (Israel) Revenue: by Geography 2020
  • Figure 19. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 20. AbbVie (United States) Revenue: by Geography 2020
  • Figure 21. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 23. Lundbeck (Denmark) Revenue, Net Income and Gross profit
  • Figure 24. Lundbeck (Denmark) Revenue: by Geography 2020
  • Figure 25. Acadia (United States) Revenue, Net Income and Gross profit
  • Figure 26. Acadia (United States) Revenue: by Geography 2020
  • Figure 27. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 30. Sun Pharma (India) Revenue: by Geography 2020
  • Figure 31. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 32. Cipla (India) Revenue: by Geography 2020
  • Figure 33. Dr. Reddy’s (India) Revenue, Net Income and Gross profit
  • Figure 34. Dr. Reddy’s (India) Revenue: by Geography 2020
  • Figure 35. Global Parkinson’s Disease Therapeutics: by Distribution Channel USD Million (2021-2026)
  • Figure 36. Global Parkinson’s Disease Therapeutics: by Drug Class USD Million (2021-2026)
  • Figure 37. South America Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 38. Asia Pacific Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 39. Europe Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 40. MEA Parkinson’s Disease Therapeutics Share (%), by Country
  • Figure 41. North America Parkinson’s Disease Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Optimus Pharma (India)
  • Teva (Israel)
  • AbbVie (United States)
  • Boehringer Ingelheim (Germany)
  • Lundbeck (Denmark)
  • Acadia (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Sun Pharma (India)
  • Cipla (India)
  • Dr. Reddy’s (India)
Additional players considered in the study are as follows:
Prevail Therapeutics (United States) , Voyager Therapeutics (United States) , Denali Therapeutics (United States)
Select User Access Type

Key Highlights of Report


May 2021 239 Pages 56 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Parkinson’s Disease Therapeutics Market Quantitative research analysis
Global Parkinson’s Disease Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Parkinson’s Disease Therapeutics Market is heading robustly to achieve new growth cycle.
The Concentration Rate of Global Parkinson’s Disease Therapeutics market is dominated by Players to generate healthy valuation by 2026.
Companies that are profiled in Global Parkinson’s Disease Therapeutics Market are Optimus Pharma (India), Teva (Israel), AbbVie (United States), Boehringer Ingelheim (Germany), Lundbeck (Denmark), Acadia (United States), GlaxoSmithKline Plc (United Kingdom), Sun Pharma (India), Cipla (India) and Dr. Reddy’s (India) etc.

Know More About Global Parkinson’s Disease Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Stye Drugs Comprehensive Study by Type (Hordeolum, Chalazion), Rout of Administration (Oral, Topical, Injectible), Prescription mode (Over-the-counter, Prescription-based), Distribution Channel (Hos...
$ 3750
Tinnitus Drug Pipeline Comprehensive Study by Type (Anti-Depressants, Anti- Anxiety, Anti-Histamines, Anti-Convulsant), Distribution Channel (Retail Pharmacies, Drug Stores, E-Commerce) Players and R...
$ 3500
Rivanol Comprehensive Study by Type (Powder, Solution), Application (Individual, Commercial), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2026
$ 3500
COPD Medicine Comprehensive Study by Type (Emphysema, Chronic bronchitis), Route of Administration (Inhalation, Enteral, Parenteral), Distribution Channel (Hospital pharmacy, Retail pharmacy, Online ...
$ 3750
Calcium Malate Comprehensive Study by End Users (Food and Beverages, Pharmaceutical, Nutraceutical, Animal Feed), Distribution Channel (Online (E-Commerce Stores), Offline (Speciality Stores, Hyper M...
$ 3650
Polypill Products Comprehensive Study by Type (Aspirin, Beta-Blockers, Diuretics, Statins, ACE-Inhibitors), Application (Blood Pressure Management, Control Cholesterol Level), Form (Capsules, Tablets...
$ 3450